ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials

American Society of Hematology. (1).
ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials.

American Society of Hematology.
"ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials
(label-accessed May 13, 2024).

"American Society of Hematology."
ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials, 13 May. 2024 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero